Invention Grant
- Patent Title: Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors
-
Application No.: US16345136Application Date: 2017-10-26
-
Publication No.: US10905688B2Publication Date: 2021-02-02
- Inventor: Jan Kehler , Lars Kyhn Rasmussen , Morten Langgård , Mikkel Jessing , Paulo Jorge Vieira Vital , Karsten Juhl
- Applicant: H. Lundbeck A/S
- Applicant Address: DE Valby
- Assignee: H. Lundbeck A/S
- Current Assignee: H. Lundbeck A/S
- Current Assignee Address: DE Valby
- Agency: Wolf, Greenfield & Sacks, P.C.
- Priority: DKPA201600659 20161028
- International Application: PCT/EP2017/077497 WO 20171026
- International Announcement: WO2018/078038 WO 20180503
- Main IPC: A61K31/4985
- IPC: A61K31/4985 ; C07D487/04 ; A61P25/28 ; A61P25/22 ; A61P25/18 ; A61P25/24 ; A61K31/5377 ; A61K31/553 ; A61K45/06 ; A61K31/55
![Combinations comprising substituted imidazo[1,5-α]pyrazinones as PDE1 inhibitors](/abs-image/US/2021/02/02/US10905688B2/abs.jpg.150x150.jpg)
Abstract:
The present invention provides combination treatments comprising compounds of Formula (I): that are PDE1 enzyme inhibitors and other compounds useful in the treatment of psychiatric and/or cognitive disorders such as for example Attention Deficit Hyperactivity Disorder (ADHD), depression, anxiety, narcolepsy, schizophrenia, cognitive impairment or cognitive impairment associated with schizophrenia (CIAS). Separate aspects of the invention are directed to the combined use of said compounds for the treatment of psychiatric and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of psychiatric and/or cognitive disorders.
Public/Granted literature
- US20190282571A1 COMBINATION TREATMENTS COMPRISING ADMINISTRATION OF IMIDAZOPYRAZINONES Public/Granted day:2019-09-19
Information query
IPC分类: